Is Johnson & Johnson's Upcoming Split Good or Bad News for Investors?

When Johnson & Johnson (NYSE: JNJ) announced that it would be splitting its pharmaceutical and medical device businesses from its consumer health segment last month, investors were stunned. But, could this actually be a genius move on management's part? Fool contributor Rachel Warren explains, in this segment of Backstage Pass, recorded on Nov. 19. 

Continue reading

Source Fool.com